Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

Study Summary

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.

Conditions

Solid Tumors, Adult

Interventions / Drugs

DCR-PDL1

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment32 participants

Primary Completion—

Lead SponsorDicerna Pharmaceuticals, Inc., a Novo Nordisk company

Data Retrieved2026-04-11 02:55:47.366425+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.